Appointment supports accelerated growth in US OOC market

Organ-on-a-chip (OOC) company CN Bio has appointed Joe Parisi as US Director of Sales, where he will lead expansion of activities for customers looking to harness the company’s range of microphysiological systems (MPS) to meet demand for new alternative methodologies (NAMs) in preclinical drug discovery. With global demand for microphysiological systems (MPS) having accelerated, particularly in the US, his will provide a local source of expertise supporting customers to improve the human relevance of preclinical workflows and reduce animal model reliance.

With a strong track record in delivering successful sales strategies across the biotechnology sector, Joe was formerly Director of Sales for US West (acquired by Bruker Corporation in 2023), with responsibility for growing the proteomics side of the business. At Purigen Biosystems (acquired by Bionano Genomics in 2022), he was Director of West Coast Sales, overseeing commercial development and supporting the Company’s growth from start-up to commercial success over three years. He has also held senior roles at numerous life sciences organisations, including Isoplexis, NanoString Technologies, and Life Technologies. Joe has a BSc in Molecular and Cellular Biology from the University of Illinois Urbana-Champaign.

“The potential offered by CN Bio’s PhysioMimix range, substantiated by the Company’s collaborative work with the FDA, is truly transformative for the drug discovery industry, providing clinical translatability that can improve efficiency and minimize drug failures. In my new role, I look forward to harnessing my experience within the sector to support the design and implementation of a commercial strategy that will enable us to meet the significant demand for animal model alternatives here in the US,” he said

CN Bio’s chief executive officer Dr. Paul Brooks, said: “It is great to welcome Joe to the team. Throughout his career, he has repeatedly demonstrated his expertise in biotech sales, with a proven history of success across companies at all stages of growth and commercialisation. Joe’s appointment represents an important milestone in CN Bio’s growth, having successfully built a strong international presence and now looking to expand this further into the US, a key market for innovative drug discovery.”

More information online